Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells.

Zinger L, Merenbakh-Lamin K, Klein A, Elazar A, Journo S, Boldes T, Pasmanik-Chor M, Spitzer A, Rubinek T, Wolf I.

Clin Cancer Res. 2019 May 1;25(9):2900-2914. doi: 10.1158/1078-0432.CCR-18-1505. Epub 2019 Feb 7.

PMID:
30733228
2.

Klotho suppresses colorectal cancer through modulation of the unfolded protein response.

Arbel Rubinstein T, Shahmoon S, Zigmond E, Etan T, Merenbakh-Lamin K, Pasmanik-Chor M, Har-Zahav G, Barshack I, Vainer GW, Skalka N, Rosin-Arbesfeld R, Varol C, Rubinek T, Wolf I.

Oncogene. 2019 Feb;38(6):794-807. doi: 10.1038/s41388-018-0489-4. Epub 2018 Sep 19.

PMID:
30232408
3.

Tumor Suppressor Activity of Klotho in Breast Cancer Is Revealed by Structure-Function Analysis.

Ligumsky H, Rubinek T, Merenbakh-Lamin K, Yeheskel A, Sertchook R, Shahmoon S, Aviel-Ronen S, Wolf I.

Mol Cancer Res. 2015 Oct;13(10):1398-407. doi: 10.1158/1541-7786.MCR-15-0141. Epub 2015 Jun 25.

4.

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I.

Cancer Res. 2013 Dec 1;73(23):6856-64. doi: 10.1158/0008-5472.CAN-13-1197. Epub 2013 Nov 11.

Supplemental Content

Loading ...
Support Center